Prosecution Insights
Last updated: November 20, 2026
Application No. 18/364,146

FLUORINE-CONTAINING ORGANIC CHAIN GRAFTED POLYOXOMETALATE CLUSTER AND DERIVATIVE THEREOF, AND THEIR PREPARATION METHOD AND USE

Non-Final OA §102§112
Filed
Aug 02, 2023
Priority
Dec 21, 2022 — CN 202211647445.X
Examiner
PAGANO, ALEXANDER R
Art Unit
1692
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Jilin University
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
859 granted / 1093 resolved
+18.6% vs TC avg
Moderate +12% lift
Without
With
+11.7%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 2m
Avg Prosecution
46 currently pending
Career history
1147
Total Applications
across all art units

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
23.0%
-17.0% vs TC avg
§102
31.4%
-8.6% vs TC avg
§112
26.3%
-13.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1093 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-19 of H. Li et al., US 18/364,146 (Aug. 22, 2023) are pending. Claims 1-7, 10 and 12-19, to non-elected inventions of Groups (I), (II) and (IV) are withdrawn from consideration pursuant to 37 CFR 1.142(b). Claims 8, 9, and 11 are under examination on the merits. Claim 8 is in condition for allowance. Claims 9 and 11 are rejected. Election/Restrictions Applicant elected Group (III), without traverse in the Reply to Restriction Requirement filed on September 14, 2026. Group (III) Claim 8, 9 and 11 drawn to a method for preparing a fluorine-containing organic chain grafted polyoxometalate cluster derivative. Claims 1-7, 10 and 12-19, to non-elected inventions of Groups (I), (II) and (IV) are withdrawn from consideration pursuant to 37 CFR 1.142(b). The restriction/election requirement is made FINAL. Claim Rejections - 35 USC § 102 (AIA ) The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. § 102(a)(1)/(2) Rejection over M. Carraro et al., 45 Dalton Transactions, 14544-14548 (2016) (“Carraro”) Claims 9 and 11 are rejected under 35 U.S.C. 102(a)(1)/(2) as being anticipated by M. Carraro et al., 45 Dalton Transactions, 14544-14548 (2016) (“Carraro”). (i) Rejection of Claim 9 The invention of base claim 8 (and the meaning of the claim 9 terms) is discussed in detail below in Subject Matter Free of the Art of Record. Claim 9 (dependent upon claim 8) recites the following bolded product-by-process language: 9. A fluorine-containing organic chain grafted polyoxometalate cluster derivative prepared by the method according to claim 8, comprising an anionic cluster moiety and a counter cationic moiety, wherein the anionic cluster moiety comprises a lacunary polyoxometalate cluster and a fluorine-containing organic chain grafted onto the lacunary polyoxometalate cluster; and the counter cationic moiety comprises one selected from the group consisting of potassium ion, hydrogen ion, sodium ion, tetrabutylammonium bromide ion and dioctadecyldimethylammonium bromide ion. Even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. MPEP § 2113(I). The patentability of a product does not depend on its method of production. MPEP § 2113(I). If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process. MPEP § 2113(I) (citing In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985)). However, the structure implied by the process steps should be considered when assessing the patentability of product-by-process claims over the prior art. MPEP § 2113(I). Carraro teaches fluorophilic polyoxotungstates perform the selective epoxidations of internal and terminal double bonds by hydrogen peroxide (H2O2) activation in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), under mild temperature conditions Carraro at Abstract. Carraro teaches synthesis of polyoxometalate fluoroalkyl hybrid complexes by reaction of the lacunary POM precursors with organosilyl chlorides (RfSiCl3, where Rf corresponds to –(CH2)2(CF2)7CF3). For example, Carraro teaches synthesis of complex 1, (nBu4N)4[α-SiW11O39{CF3(CF2)7(CH2)2Si}2O], as summarized by the Examiner below: PNG media_image1.png 200 400 media_image1.png Greyscale Note that Carraro’s above synthesis differs from instant withdrawn claim 1 only in that a trichlorofluoroalkyl silane was employed, whereas claim 1 requires a fluoroalkyl trimethoxysilane. Specification working Example 3 (an example of the base claim 8 ion-exchange method) is summarized by the Examiner below for comparison to Carraro’s process. PNG media_image2.png 200 400 media_image2.png Greyscale Specification at page 12, [0083]-[0084]/ Carraro’s process to prepare complex (1) does not involve the claim 8 ion exchange steps (per above-summarized specification Example 3). However, the claim 8 process does not impart any structure to the claim 9 “fluorine-containing organic chain grafted polyoxometalate cluster derivative” that can differentiate the claim 9 product from Carraro complex (1). MPEP § 2113(I). And Carraro complex (1) meets every claim 9 chemical structure limitation, where the counter cationic moiety comprises tetrabutylammonium bromide. As such, product-by-process claim 9 is anticipated by Carraro complex (1). MPEP § 2113(I). (ii) Rejection of Claim 11 Method claim 11, dependent upon claim 9 recites, recites the single step of “using” the claim 9 product: 11. A method for preparing a proton exchange membrane or a surfactant, comprising using the fluorine-containing organic chain grafted polyoxometalate cluster derivative according to claim 9. The single step of “using the fluorine-containing organic chain grafted polyoxometalate cluster derivative according to claim 9” is a clear method step. See MPEP § 2173.05(q) (discussing Ex parte Porter, 25 USPQ2d 1144 (Bd. Pat. App. & Inter. 1992), where the Board held that a claim which clearly recited the step of "utilizing" was not indefinite under 35 U.S.C. 112, second paragraph); Ex parte Porter, 25 USPQ2d 1147 (“[c]ontrary to the examiner's assertion that claim 6 has no method step, the claim clearly recites the step of ‘utilizing’”).1 With respect to “using”, The specification teaches that, “in some embodiments”, the hydrogen-type fluorine-containing organic chain grafted polyoxometalate cluster is useful in a proton exchange membrane, by mixing with a solution of a perfluorosulfonic acid membrane [e.g., Nafion], and then the resulting mixture is cast to form a membrane to obtain a hydrogen-type fluorine-containing organic chain grafted polyoxometalate cluster hybrid perfluorosulfonic acid membrane, which is used in a proton exchange membrane in a fuel cell. Specification at page 9, [0064]; see also, G. He et al., 27 Advanced Materials, 5280-5295 (2015) (at page 5280 teaching that the ion-exchange membrane (IEM) is a critical efficiency-determining component of polymer electrolyte fuel cells (PEFCs). (iia) The Claim 11 Preamble Is Not Interpreted as a Claim Limitation The claim 11 preamble “[a] method for preparing a proton exchange membrane or a surfactant” is not interpreted as a claim limitation that can differentiate over Carraro, because the claim 11 body fully sets forth all of the limitations, and the preamble merely states the purpose or intended use of the invention, rather than any distinct definition of any of the claimed invention’s limitations. MPEP § 2112.02(II) (citing Rowe v. Dror, 112 F.3d 473, 478, 42 USPQ2d 1550, 1553 (Fed. Cir. 1997).2 (iib) Carraro Meets Every Claim 11 Limitation Carraro teaches that in using complex (1), CF3CH(OH)CF3 (0.6 ml), polyoxometalate (POM) (0.8 μmol) and the substrate (0.5 mmol) were mixed, and 0.1 mmol of hydrogen peroxide (35 or 70% aqueous solutions were used) was added, in a closed glass reactor. Carraro at Supplementary page 3. Carraro thus meets the claim 11 limitation of “using the fluorine-containing organic chain grafted polyoxometalate cluster derivative according to claim 9”. In this regard, the plain meaning of claim 11 step of “using”, is very broad and reads, for example, on any physical manipulation of Carraro complex (1); for instance, the mere transfer of Carraro complex (1) to a reaction vessel reads on the step of “using”. Subject Matter Free of the Art of Record Claim 8 is free of the art of record. The Closest Art of Record is M. Carraro et al., 45 Dalton Transactions, 14544-14548 (2016) (“Carraro”). The Claimed Invention Independent claim 8 is directed to a one-step method for preparing a fluorine-containing organic chain grafted polyoxometalate cluster derivative comprising mixing a fluorine-containing organic chain grafted polyoxometalate cluster with a counter reagent, where per claim 8, Claim 8 . . . the fluorine-containing organic chain grafted polyoxometalate cluster comprises a lacunary polyoxometalate cluster and a fluorine-containing organic chain grafted onto the lacunary polyoxometalate cluster . . . Per the specification, the “counter reagent” exchanges the starting fluorine-containing polyoxometalate cluster counter ions to give “a fluorine-containing organic chain grafted polyoxometalate cluster derivative containing different counter ions”. Specification at page 3, [0018]. As background, polyoxometalates (POMs) are anionic metal oxide clusters of Mo, W, V and Nb and have applications in catalysis and other fields. H. Miras et al., 41 Chemical Society Reviews, 7403-7430 (2012) (“Miras”); J. Borrás-Almenar et al., Polyoxometalate Molecular Science, 1-78 (2001) (see page 4) (Borrás-Almenar”). A lacunary polyoxometalate is where one or more [MOx] units are removed from the plenary structure to form a defect so as to possess a vacant, reactive sites for metal atoms or organic ligands. C. Li et al., 60 Angew. Chem. Int. Ed. 6960-6964 (2021) (see page 6960) (“Li”). Lacunary POMs are key precursors of functional polyoxometalates, that is, by introducing metal species or organic ligands into their vacant/defect sites, a vast diversity of structures with fascinating properties have been constructed. Li at page 6960, col. 1. Lacunary polyoxometalates are synthesized by controlling the equilibrium in aqueous solvents through empirical control of pH, concentration, temperature, and/or reagent mixing ratio. Li at page 6960, col. 1); see also, P. Gouzerh et al., 98 Chemical Reviews, 77-111 (1998) (see page 92, col. 2); M. da Silva et al., 148 Catalyst Letters, 2516-2527 (2018). Claim 8 is exemplified by specification working Examples 2 and 3, which are summarized by the Examiner below, where the potassium ion of the staring lacunary K4[SiW11O39(SiC2H4(C2F4)2)2O polyoxometalate is exchanged with hydrogen and the resulting hydrogen species exchanged with TBA. Specification at pages 11-12 (Examples 2 and 3). PNG media_image3.png 200 400 media_image3.png Greyscale Specification at pages 11-12 (Examples 2 and 3). The starting K4[SiW11O39(SiC2H4(C2F4)2)2O (as used in Examples 2 and 3) is prepared in specification Example 1 as follows. Specification at page 11, [0078]. PNG media_image4.png 200 400 media_image4.png Greyscale Specification at page 11, [0078]. The specification teaches the hydrogen-type fluorine-containing organic chain grafted polyoxometalate cluster is useful in a proton exchange membrane, by mixing with a solution of a perfluorosulfonic acid membrane [e.g., Nafion], and then the resulting mixture is cast to form a membrane to obtain a hydrogen-type fluorine-containing organic chain grafted polyoxometalate cluster hybrid perfluorosulfonic acid membrane, which is used in a proton exchange membrane in a fuel cell. Specification at page 9, [0064]; see also, G. He et al., 27 Advanced Materials, 5280-5295 (2015) ( at page 5280 teaching that the ion-exchange membrane (IEM) is a critical efficiency-determining component of polymer electrolyte fuel cells (PEFCs). M. Carraro et al., 45 Dalton Transactions, 14544-14548 (2016) (“Carraro”) Carraro teaches fluorophilic polyoxotungstates perform the selective epoxidations of internal and terminal double bonds by hydrogen peroxide (H2O2) activation in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), under mild temperature conditions Carraro at Abstract. Carraro teaches synthesis of polyoxometalate fluoroalkyl hybrid complexes by reaction of the lacunary POM precursors with organosilyl chlorides (RfSiCl3, where Rf corresponds to –(CH2)2(CF2)7CF3); for example, complex 1, (nBu4N)4[α-SiW11O39{CF3(CF2)7(CH2)2Si}2O], as summarized by the Examiner below: PNG media_image1.png 200 400 media_image1.png Greyscale Carraro at Supplementary pages 2-4; Carraro at page 14545, col. 1, Fig. 1. Differences between Claim 8 and Carraro It is first noted (as pointed out in the Examiner’s scheme above) that Carraro’s complex (1) meets the claim 8 limitation of Claim 8 . . . a fluorine-containing organic chain grafted polyoxometalate . . . wherein: the fluorine-containing organic chain grafted polyoxometalate cluster comprises a lacunary polyoxometalate cluster and a fluorine-containing organic chain grafted onto the lacunary polyoxometalate cluster . . . However, instant claim 8 differs from Carraro’s synthesis of (nBu4N)4[α-SiW11O39{CF3(CF2)7(CH2)2Si}2O] in that Carraro does not teach the claim 8 step of: Claim 8 . . . mixing a fluorine-containing organic chain grafted polyoxometalate cluster with a counter reagent to obtain a second mixture; and subjecting the second mixture to replacement to obtain a fluorine-containing organic chain grafted polyoxometalate cluster derivative containing different counter ions . . . Claim 8 Is Not Obvious in View of Carraro Carraro does not teach or suggest treating the polyoxometalate fluoroalkyl hybrid complexes (e.g., complex 1, (nBu4N)4[α-SiW11O39{CF3(CF2)7(CH2)2Si}2O]) with a “counter regent” to exchange the counter ion (e.g., (nBu4N)4) with another to obtain the complex having a different counterion. In this regard, Carraro is directed to a different application (use of the complexes as catalysts), whereas the instant specification teaches application in proton exchange membranes for use in batteries/fuel cells. Specification at page 9, [0064]. Neither Carraro nor secondary art teaches that Carraro’s polyoxometalate fluoroalkyl hybrid complexes have application in exchange membranes. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALEXANDER R PAGANO whose telephone number is (571)270-3764. The examiner can normally be reached 8:00 AM through 5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. ALEXANDER R. PAGANO Examiner Art Unit 1692 /ALEXANDER R PAGANO/Primary Examiner, Art Unit 1692 1 Note however, that attempts to claim a process without setting forth any steps involved in the process generally raises an issue of indefiniteness under 35 U.S.C. 112(b). MPEP § 2173.05(q). For example, a claim reciting the preamble: "[a] process for using monoclonal antibodies of claim 4 to isolate and purify human fibroblast interferon" was held to be indefinite because it merely recites a use without any active, positive steps delimiting how this use is actually practiced. MPEP § 2173.05(q) (citing Ex parte Erlich, 3 USPQ2d 1011 (Bd. Pat. App. & Inter. 1986). 2 As a general rule preamble language is not treated as limiting. Arctic Cat Inc. v. GEP Power Prods., Inc., 919 F.3d 1320, 1327 (Fed. Cir. 2019). Exceptions arise where, for example, the preamble (1) recites essential structure or steps; (2) provides antecedent basis for terms in the claim body; or (3) was relied on during prosecution to distinguish the claimed invention from prior art. Catalina Mktg. Int’l, Inc. v. Cool savings.com, Inc., 289 F.3d 801, 808 (Fed. Cir. 2002). If the body of a claim fully and intrinsically sets forth all of the limitations of the claimed invention, and the preamble merely states, for example, the purpose or intended use of the invention, rather than any distinct definition of any of the claimed invention’s limitations, then the preamble is not considered a limitation and is of no significance to claim construction. MPEP § 2112.02(II) (citing Rowe v. Dror, 112 F.3d 473, 478, 42 USPQ2d 1550, 1553 (Fed. Cir. 1997) ("where a patentee defines a structurally complete invention in the claim body and uses the preamble only to state a purpose or intended use for the invention, the preamble is not a claim limitation")).
Read full office action

Prosecution Timeline

Aug 02, 2023
Application Filed
Nov 05, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780861
PYRAZOLE COBALT-BASED METAL-ORGANIC FRAMEWORK MATERIAL WITH DYNAMIC PORE SIZE, METHOD FOR MAKING THE SAME, AND USE IN SULFUR HEXAFLUORIDE CAPTURE
1y 12m to grant Granted Nov 03, 2026
Patent 12774263
RECYCLE CONTENT (C4)ALKANOIC ACID
4y 9m to grant Granted Oct 27, 2026
Patent 12767672
METHODS TO PRODUCE ORGANOTIN COMPOSITIONS WITH CONVENIENT LIGAND PROVIDING REACTANTS
12m to grant Granted Oct 20, 2026
Patent 12760046
NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS
3y 0m to grant Granted Oct 13, 2026
Patent 12753323
FLUORINE-CONTAINING ETHER COMPOUND, SURFACE TREATMENT AGENT, FLUORINE-CONTAINING ETHER COMPOSITION, COATING LIQUID, ARTICLE, AND COMPOUND
4y 6m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
90%
With Interview (+11.7%)
2y 2m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1093 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month